Demystifying “mosaic” outcomes

Demystifying “mosaic” outcomes
The use of preimplantation genetic testing for aneuploidy (PGT-A) has increased in recent years following the publication of trials demonstrating improved outcomes per transfer in good prognosis patients (1). Though not used in those trials, the PGT-A field rapidly adopted next generation sequencing (NGS) as the most common method. Cell line studies demonstrated that NGS can more reliably predict whether a model embryo biopsy contains a mix of normal and abnormal cells, leading to the mosaic diagnosis becoming part of the PGT-A lexicon.
Source: fertstert.org